Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
Phase 1
Completed
- Conditions
- AnemiaCongestive Heart Failure
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117247
Study to Evaluate Effectiveness of Aranesp®
Phase 4
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117130
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Phase 4
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2423
- Registration Number
- NCT00117117
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
Phase 4
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117104
Study of Transplant Related Anemia Treated With Aranesp® (STRATA)
Phase 4
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117065
A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia
Phase 4
Completed
- Conditions
- AnemiaNeoplasms
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1500
- Registration Number
- NCT00117039
Aranesp® Monthly Preference Study - 2
Phase 4
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2008-09-30
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117078
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
Phase 3
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00116701
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2009-05-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 371
- Registration Number
- NCT00115167
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
Phase 4
Completed
- Conditions
- Chronic Renal FailureAnemia
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00111995
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath